Conversion from sustained release carbidopa/levodopa to Stalevo® in Parkinson's disease patients

被引：0

|

作者：

Pahwa, R

Lyons, KE

机构：

来源：

MOVEMENT DISORDERS | 2005年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P237

引用

收藏

页码：S71 / S71

页数：1

相关论文

共 50 条

[21] IPX203 dose conversion from immediate-release carbidopa-levodopa, in Parkinson's disease patients with motor fluctuations
Hauser, R.
Espay, A.
Ondo, W.
Safirstein, B.
Moore, H.
Kumar, R.
Banisadr, G.
Fisher, S.
MOVEMENT DISORDERS, 2022, 37 : S331 - S332
[22] New levodopa/carbidopa/entacapone tablets (Stalevo®) provide better quality of life for Parkinson's disease patients and save costs to the society
Findley, L
Turunen, H
Apajasalo, M
Lees, A
MOVEMENT DISORDERS, 2005, 20 : S121 - S122
[23] Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo®)
Solla, Paolo
Cannas, Antonino
Marrosu, Francesco
Marrosu, Maria Giovanna
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 483 - 490
[24] Levodopa/carbidopa/entacapone in Parkinson's disease
Seeberger, Lauren C.
Hauser, Robert A.
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2009, 9 (07) : 929 - 940
[25] Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet®), sustained-release carbidopa-levodopa (Sinemet® CR), and carbidopa-levodopa-entacapone (Stalevo®)
Hsu, Ann
Yao, Hsuan-Ming
Gupta, Suneel
Modi, Nishit B.
JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (09): : 995 - 1003
[26] Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease
Delea, Thomas E.
Thomas, Simu K.
Hagiwara, May
Mancione, L.
CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (07) : 1543 - 1552
[27] Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson's disease patients: Dosing patterns
Morgan, J.
Stacy, M.
Rubens, R.
Khanna, S.
Gupta, S.
MOVEMENT DISORDERS, 2016, 31 : S659 - S659
[28] Comparison of 200 mg retarded release levodopa/carbidopa -: with 150 mg levodopa/carbidopa/entacapone application:: pharmacokinetics and efficacy in patients with Parkinson's disease
Mueller, T.
Ander, L.
Kolf, K.
Woitalla, D.
Muhlack, S.
JOURNAL OF NEURAL TRANSMISSION, 2007, 114 (11) : 1457 - 1462
[29] Comparison of 200 mg retarded release levodopa/carbidopa – with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson’s disease
T. Müller
L. Ander
K. Kolf
D. Woitalla
S. Muhlack
Journal of Neural Transmission, 2007, 114 : 1457 - 1462
[30] DUODENAL CARBIDOPA/LEVODOPA: AN OPPORTUNITY FOR ADVANCED PARKINSON'S DISEASE PATIENTS
Gayoso Rey, Monica
Lopez Diaz, Luis Manuel
ATENCION FARMACEUTICA, 2013, 15 (05): : 362 - 364

← 1 2 3 4 5 →